In part 4 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about insurance coverage of SGLT-2 drugs and the challenges for patients with heart and kidney issues.

In part 5 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about studies on the use of SGLT in other populations — people without diabetes, people with kidney disease, etc.